
AbbVie (NYSE:ABBV) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release. Th…
ABBV is up 0.39% today. Volume is 4.32M vs a 30-day average of 4.87M (0.89x).
AbbVie Inc. is scheduled to report earnings Fri, Oct 30, 2026 · before open. Analysts expect EPS of $3.83 on revenue of about $17.66B. Stocks often move sharply on earnings day.

AbbVie (NYSE:ABBV) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release. Th…

Key Stats for AbbVie StockCurrent Price: $285. 64Target Price (Mid): ~$364Street Target: ~$285Potential Total Return: ~27%Annualized IRR: ~6% / year__Now Live: Discover how much u…

AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US…

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moder…
AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with modera…